One new study has put a familiar weight-loss drug controversy back in the spotlight: GLP-1 medicines were linked to roughly a 30 percent lower breast cancer incidence, but the finding is still observational and not proof of prevention.
Quick Take
- Researchers at Penn Medicine analyzed more than 110,000 women ages 45 to 80 and found lower breast cancer odds among GLP-1 users.[2][3]
- The strongest reported reductions were 35.1 percent in the full analysis and 30.5 percent in the matched cohort.[2][3]
- Lead researchers and outside experts stressed that the result is observational, so it cannot prove the drugs caused the lower risk.[2][3]
- Other breast cancer research on GLP-1 medicines is emerging, but the broader evidence remains early and mixed.[1][4]
What the Penn Study Found
Penn Medicine said the study reviewed electronic health records from women who had breast imaging and compared GLP-1 users with nonusers.[2] The analysis found about 35.1 percent lower odds of breast cancer in the full sample and 30.5 percent lower odds in the matched cohort, which is the source of the “about 30 percent lower risk” headline.[2][3]
The research team reported that the association held after matching on major factors such as age, body mass index, diabetes status, race, ethnicity, and breast density.[2][3] That matters because obesity and diabetes can affect cancer risk, and matching helps reduce some bias, but it does not eliminate the limits of retrospective data.[2][3]
Why Experts Say Caution Still Matters
The same researchers described the work as observational and said it does not definitively confirm an association between GLP-1 medicines and reduced breast cancer incidence.[2][3] ABC News quoted the lead author saying the findings are a starting point for further research rather than proof that the drugs directly cut cancer risk.[4]
That caution is important because women were not randomly assigned to take the medications, and the study could not fully measure other influences such as exercise, alcohol use, family history, genetic risk, or socioeconomic status.[2][3] Those missing variables can create a false impression of protection if the drug users differ from nonusers in ways that also affect breast cancer risk.[2][3]
How This Fits the Bigger GLP-1 Debate
This result adds to a growing body of cancer-related GLP-1 research that now spans incidence, recurrence, and survival, but the evidence is not settled.[1][4] Memorial Sloan Kettering Cancer Center notes that these drugs are already being studied for possible effects on obesity-related cancers, while breast cancer groups say the field is still in early stages.[1]
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings…
— The Something Guy 🇿🇦 (@thesomethingguy) June 6, 2026
Other studies cited in the research package point in different directions, including work that found no increased breast cancer risk in a large treated group and other early reports suggesting possible benefits in breast cancer outcomes.[3][4] For patients, the practical takeaway is not that Ozempic or similar drugs are cancer-prevention pills, but that researchers may be uncovering another reason body weight and metabolic health matter for cancer risk.[1][3]
Sources:
[1] Web – Ozempic and similar weight-loss drugs linked to 30% lower breast …
[2] Web – Ozempic, Wegovy: GLP-1 Drugs Lower Breast Cancer Risk by 30%
[3] Web – GLP-1 use linked to lower breast cancer incidence – Penn Medicine
[4] Web – The Impact and Safety of GLP‐1 Agents and Breast Cancer – PMC
